Journal articles: 'Docosahexaenoic acid – Testing'

1

Pike, Katharine C., Philip C. Calder, Hazel M. Inskip, Sian M. Robinson, Graham C. Roberts, Cyrus Cooper, Keith M. Godfrey, and Jane S. A. Lucas. "Maternal Plasma Phosphatidylcholine Fatty Acids and Atopy and Wheeze in the Offspring at Age of 6 Years." Clinical and Developmental Immunology 2012 (2012): 1–13. http://dx.doi.org/10.1155/2012/474613.

Full text

Abstract:

Variation in exposure to polyunsaturated fatty acids (PUFAs) might influence the development of atopy, asthma, and wheeze. This study aimed to determine whether differences in PUFA concentrations in maternal plasma phosphatidylcholine are associated with the risk of childhood wheeze or atopy. For 865 term-born children, we measured phosphatidylcholine fatty acid composition in maternal plasma collected at 34 weeks’ gestation. Wheezing was classified using questionnaires at 6, 12, 24, and 36 months and 6 years. At age of 6 years, the children underwent skin prick testing, fractional exhaled nitric oxide (FENO) measurement, and spirometry. Maternaln-6 fatty acids and the ratio ofn-3 ton-6 fatty acids were not associated with childhood wheeze. However, higher maternal eicosapentaenoic acid, docosahexaenoic acid, and totaln-3 fatty acids were associated with reduced risk of non-atopic persistent/late wheeze (RR 0.57, 0.67 and 0.69, resp.P=0.01, 0.015, and 0.021, resp.). Maternal arachidonic acid was positively associated with FENO (P=0.024). A higher ratio of linoleic acid to its unsaturated metabolic products was associated with reduced risk of skin sensitisation (RR 0.82,P=0.013). These associations provide some support for the hypothesis that variation in exposure ton-6 andn-3 fatty acids during pregnancy influences the risk of childhood wheeze and atopy.

APA, Harvard, Vancouver, ISO, and other styles

2

Hallahan, Brian, Timothy Ryan, Joseph R. Hibbeln, Ivan T. Murray, Shauna Glynn, Christopher E. Ramsden, John Paul SanGiovanni, and John M. Davis. "Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression." British Journal of Psychiatry 209, no. 3 (September 2016): 192–201. http://dx.doi.org/10.1192/bjp.bp.114.160242.

Full text

Abstract:

BackgroundTrials evaluating efficacy of omega-3 highly unsaturated fatty acids (HUFAs) in major depressive disorder report discrepant findings.AimsTo establish the reasons underlying inconsistent findings among randomised controlled trials (RCTs) of omega-3 HUFAs for depression and to assess implications for further trials.MethodA systematic bibliographic search of double-blind RCTs was conducted between January 1980 and July 2014 and an exploratory hypothesis-testing meta-analysis performed in 35 RCTs including 6665 participants receiving omega-3 HUFAs and 4373 participants receiving placebo.ResultsAmong participants with diagnosed depression, eicosapentaenoic acid (EPA)-predominant formulations (>50% EPA) demonstrated clinical benefits compared with placebo (Hedge's G = 0.61, P<0.001) whereas docosahexaenoic acid (DHA)-predominant formulations (>50% DHA) did not. EPA failed to prevent depressive symptoms among populations not diagnosed for depression.ConclusionsFurther RCTs should be conducted on study populations with diagnosed or clinically significant depression of adequate duration using EPA-predominant omega-3 HUFA formulations.

APA, Harvard, Vancouver, ISO, and other styles

3

Tully, A. M., H. M. Roche, R. Doyle, C. Fallon, I. Bruce, B. Lawlor, D. Coakley, and M. J. Gibney. "Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case–control study." British Journal of Nutrition 89, no. 4 (April 2003): 483–89. http://dx.doi.org/10.1079/bjn2002804.

Full text

Abstract:

Lown-3 polyunsaturated fatty acid (PUFA) status may be associated with neuro-degenerative disorders, in particular Alzheimer's disease, which has been associated with poor dietary fish orn-3 PUFA intake, and low docosahexaenoic acid (DHA) status. The present case–control study used an established biomarker ofn-3 PUFA intake (serum cholesteryl ester-fatty acid composition) to determinen-3 PUFA status in patients with Alzheimer's disease, who were free-living in the community. All cases fulfilled the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association criteria for Alzheimer's disease. Detailed neuropsychological testing and neuroimaging established the diagnosis in all cases. The subjects (119 females and twenty-nine males) aged 76·5 (SD 6·6) YEARS HAD A CLINICAL DEMENTIA RATING (CDR) OF 1 (sd 0·62) and a mini mental state examination (MMSE) score of 19·5 (sd 4·8). The control subjects (thirty-six females and nine males) aged 70 (sd 6·0) years were not cognitively impaired (defined as MMSE score <24): they had a mean MMSE score of 28·9 (sd 1·1). Serum cholesteryl ester-eicosapentaenoic acid and DHA levels were significantly lower (P<0·05 andP<0·001 respectively) in all MMSE score quartiles of patients with Alzheimer's disease compared with control values. Serum cholesteryl ester-DHA levels were progressively reduced with severity of clinical dementia. DHA levels did not differ in patients with Alzheimer's disease across age quartiles: all were consistently lower than in control subjects. Step-wise multiple regression analysis showed that cholesteryl ester-DHA and total saturated fatty acid levels were the important determinants of MMSE score and CDR. It remains to be determined whether low DHA status in Alzheimer's disease is a casual factor in the pathogenesis and progression of Alzheimer's disease.

APA, Harvard, Vancouver, ISO, and other styles

4

Suseno, Sugeng Heri, Agoes Mardiono Jacoeb, Hanani Putri Yocinta, and Kamini Kamini. "Quality of Comercial Import Fish Oil (Softgel) in Central Java." Jurnal Pengolahan Hasil Perikanan Indonesia 21, no. 3 (December 28, 2018): 556. http://dx.doi.org/10.17844/jphpi.v21i3.24743.

Full text

Abstract:

Fish oil is a source of omega-3s, specifically EPA (Eicosapentaenoic acid) and DHA (Docosahexaenoic acid). These fatty acids play an important role for human health. Commercial fish oil production is increasing, but most of the products do not meet IFOS standards. This is a challenge for producers to produce standardized fish oil. The aim of this research was to identify and determining quality of softgel commercial fish oil in Central Java areas based on International Fish Oil Standards (IFOS). The method used was the treatment of differences in the area of origin of commercial fish oil purchases followed by testing the peroxide value, anisidine value, and total oxidation, fatty acid profile, and analysis of free fatty acids. The results showed that the percentage of free fatty acids, peroxide values, anisidine values, and total oxidation values that met IFOS standards were 37 % (3 of 8 samples), 17 % (1 of 8 samples), 83 % (7 of 8 samples) and 50 % (4 out of 8 samples). The best fish oil that fulfil all IFOS parameters has been the sample fish oil E from Tegal. Fish oil D from Tegal has the highest content of omega-3, EPA, and DHA, with values<br />of 83.65%, 56.57%, and 26.74% respectively.

APA, Harvard, Vancouver, ISO, and other styles

5

Miller, Shane M., Aaron J. Zynda, Meagan J. Sabatino, Henry B. Ellis, and Robert Dimeff. "DOCOSAHEXAENOIC ACID (DHA) FOR THE TREATMENT OF PEDIATRIC SPORT-RELATED CONCUSSION: RESULTS OF A FEASIBILITY TRIAL." Orthopaedic Journal of Sports Medicine 7, no. 3_suppl (March 1, 2019): 2325967119S0000. http://dx.doi.org/10.1177/2325967119s00004.

Full text

Abstract:

Introduction: The rate of sport-related concussion (SRC) has increased steadily over the past two decades in the pediatric population. Docosahexaenoic acid (DHA), an Omega-3 fatty acid important for brain development in children, may aid in recovery following SRC. The purpose of this study was to determine the feasibility, outcomes, and safety of DHA as early treatment for SRC in pediatrics. Methods: A double-blind, randomized, placebo-controlled feasibility trial was conducted. Inclusion criteria were ages 14-18 and SRC within 4 days of enrollment. Exclusion criteria included taking DHA, radiographic evidence of TBI, participation in motorized sports, or previous concussion within past 6 months. Following diagnosis of concussion and initiation of standard treatment, subjects were randomized in a 1:1 fashion to DHA or a placebo and were instructed to take 2 capsules twice daily for 12 weeks. DHA capsules contained a total of 2000 mg of DHA/day and PLACEBO capsules contained corn and soy oil. Both were flavored with masking agents. Subjects were followed prospectively. Standard clinical assessments, SCAT-3 symptoms, ImPACT scores, BESS scores, adverse effects, and drug compliance was collected at enrollment, 1-week, 2-weeks, 4-weeks and 12-weeks. Demographics, day of injury symptoms, injury characteristics, and sport played were also collected. Subjects who demonstrated normal neurocognitive testing, complete symptom resolution and were cleared to begin a return to play (RTP) progression prior to the 4-week follow-up visit were permitted to forgo additional study visits, but requested to return for the 12-week visit. Groups were compared using Mann-Whitney tests for continuous variables and chi-square tests for categorical variables. Results: 40 subjects were enrolled; 20 in the DHA group (mean age: 16.02 years; 65% male) and 20 in the PLACEBO group (mean age: 15.97 years; 70% male). No significant differences in demographics, sport, symptoms, ImPACT scores, or BESS scores at enrollment were noted between groups. 25 (62.5%) subjects completed the 12-week visit. Overall drug compliance was 61.57% in the DHA group compared to 66.34% in the PLACEBO group (p=0.727). Subjects in the DHA group were symptom-free 4 days earlier than the PLACEBO group (16.1 vs. 20.9 days, p=0.082), demonstrated normal ImPACT neurocognitive testing (12.2 vs. 16.8 days, p=0.382), and were cleared to begin a RTP progression (21.4 vs. 23.4 days, p=0.115) sooner than those in the PLACEBO group. Two adverse effects were noted in the DHA group. One event was determined to be unrelated to the study. The second event was drug-related eructation and considered minor. No adverse effects were reported in the PLACEBO group. Conclusion: This study demonstrated that use of high-dose DHA for treatment of SRC in pediatrics is feasible and safe. DHA may allow for a faster symptom-free state and for an earlier return to play, but a large-scale trial is needed.

APA, Harvard, Vancouver, ISO, and other styles

6

Prieto, Cristina, and Jose M. Lagaron. "Nanodroplets of Docosahexaenoic Acid-Enriched Algae Oil Encapsulated within Microparticles of Hydrocolloids by Emulsion Electrospraying Assisted by Pressurized Gas." Nanomaterials 10, no. 2 (February 6, 2020): 270. http://dx.doi.org/10.3390/nano10020270.

Full text

Abstract:

Long chain polyunsaturated omega-3 fatty acids (PUFAs), namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are important functional ingredients due to their well-documented health benefits, but highly susceptible to oxidation. One of the most promising approaches to preserve bioactives is their encapsulation within protective matrices. In this paper, an innovative high throughput encapsulation technique termed as emulsion electrospraying assisted by pressurized gas (EAPG) was used to encapsulate at room temperature nanodroplets of algae oil into two food hydrocolloids, whey protein concentrate and maltodextrin. Spherical encapsulating particles with sizes around 5 µm were obtained, where the oil was homogeneously distributed in nanometric cavities with sizes below 300 nm. Peroxide values under 5 meq/kg, demonstrated that the oil did not suffer from oxidation during the encapsulation process carried out at room temperature. An accelerated stability assay against oxidation under strong UV light was performed to check the protective capacity of the different encapsulating materials. While particles made from whey protein concentrate showed good oxidative stability, particles made from maltodextrin were more susceptible to secondary oxidation, as determined by a methodology put forward in this study based on ATR-FTIR spectroscopy. Further organoleptic testing performed with the encapsulates in a model food product, i.e., milk powder, suggested that the lowest organoleptic impact was seen for the encapsulates made from whey protein concentrate. The obtained results demonstrate the potential of the EAPG technology using whey protein concentrate as the encapsulating matrix, for the stabilization of sensitive bioactive compounds.

APA, Harvard, Vancouver, ISO, and other styles

7

Geppert, Julia, Hans Demmelmair, Gerard Hornstra, and Berthold Koletzko. "Co-supplementation of healthy women with fish oil and evening primrose oil increases plasma docosahexaenoic acid, γ-linolenic acid and dihomo-γ-linolenic acid levels without reducing arachidonic acid concentrations." British Journal of Nutrition 99, no. 2 (February 2008): 360–69. http://dx.doi.org/10.1017/s0007114507801577.

Full text

Abstract:

Fish oil supplementation during pregnancy not only improves maternal and neonatal DHA status, but often reduces γ-linolenic acid (GLA), dihomo-GLA (DGLA), and arachidonic acid (ARA) levels also, which may compromise foetal and infant development. The present study investigated the effects of a fish oil/evening primrose oil (FSO/EPO) blend (456 mg DHA/d and 353 mg GLA/d) compared to a placebo (mixture of habitual dietary fatty acids) on the plasma fatty acid (FA) composition in two groups of twenty non-pregnant women using a randomised, double-blind, placebo-controlled parallel design. FA were quantified in plasma total lipids, phospholipids, cholesterol esters, and TAG at weeks 0, 4, 6 and 8. After 8 weeks of intervention, percentage changes from baseline values of plasma total lipid FA were significantly different between FSO/EPO and placebo for GLA (+49·9 % v. +2·1 %, means), DGLA (+13·8 % v. +0·7 %) and DHA (+59·6 % v. +5·5 %), while there was no significant difference for ARA ( − 2·2 % v. − 5·9 %). FA changes were largely comparable between plasma lipid fractions. In both groups three subjects reported mild adverse effects. As compared with placebo, FSO/EPO supplementation did not result in any physiologically relevant changes of safety parameters (blood cell count, liver enzymes). In women of childbearing age the tested FSO/EPO blend was well tolerated and appears safe. It increases plasma GLA, DGLA, and DHA levels without impairing ARA status. These data provide a basis for testing this FSO/EPO blend in pregnant women for its effects on maternal and neonatal FA status and infant development.

APA, Harvard, Vancouver, ISO, and other styles

8

Zhang, Alexis Ceecee, and Laura E. Downie. "Preliminary Validation of a Food Frequency Questionnaire to Assess Long-Chain Omega-3 Fatty Acid Intake in Eye Care Practice." Nutrients 11, no. 4 (April 11, 2019): 817. http://dx.doi.org/10.3390/nu11040817.

Full text

Abstract:

Clinical recommendations relating to dietary omega-3 essential fatty acids (EFAs) should consider an individual’s baseline intake. The time, cost, and practicality constraints of current techniques for quantifying omega-3 levels limit the feasibility of applying these methods in some settings, such as eye care practice. This preliminary validation study, involving 40 adults, sought to assess the validity of a novel questionnaire, the Clinical Omega-3 Dietary Survey (CODS), for rapidly assessing long-chain omega-3 intake. Estimated dietary intakes of long-chain omega-3s from CODS correlated with the validated Dietary Questionnaire for Epidemiology Studies (DQES), Version 3.2, (Cancer Council Victoria, Melbourne, Australia) and quantitative assays from dried blood spot (DBS) testing. The ‘method of triads’ model was used to estimate a validity coefficient (ρ) for the relationship between the CODS and an estimated “true” intake of long-chain omega-3 EFAs. The CODS had high validity for estimating the ρ (95% Confidence Interval [CI]) for total long-chain omega-3 EFAs 0.77 (0.31–0.98), docosahexaenoic acid 0.86 (0.54–0.99) and docosapentaenoic acid 0.72 (0.14–0.97), and it had moderate validity for estimating eicosapentaenoic acid 0.57 (0.21–0.93). The total long-chain omega-3 EFAs estimated using the CODS correlated with the Omega-3 index (r = 0.37, p = 0.018) quantified using the DBS biomarker. The CODS is a novel tool that can be administered rapidly and easily, to estimate long-chain omega-3 sufficiency in clinical settings.

APA, Harvard, Vancouver, ISO, and other styles

9

Anzalone, Anthony, Aaron Carbuhn, Lauren Jones, Ally Gallop, Alex Smith, Palmer Johnson, Lisa Swearingen, et al. "The Omega-3 Index in National Collegiate Athletic Association Division I Collegiate Football Athletes." Journal of Athletic Training 54, no. 1 (January 1, 2019): 7–11. http://dx.doi.org/10.4085/1062-6050-387-18.

Full text

Abstract:

Context The essential omega-3 fatty acids (ω-3 FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exhibit vital biological roles and are critical for cardiovascular and neurologic health. Compared with the general population, football athletes may be at an increased risk of cardiovascular disease. Further, those same athletes are also exposed to repetitive head impacts, which may lead to long-term neurologic deficits. Both diets high in ω-3 FAs and supplementation with ω-3 FAs have been reported to reduce the risk of cardiovascular disease, and early evidence suggests a potential neuroprotective effect of supplementation. Objective To determine the (1) erythrocyte content of DHA and EPA, as measured by the Omega-3 Index, expressed as a percentage of total fatty acids, in National Collegiate Athletic Association Division I football athletes and (2) distribution across the Omega-3 Index risk zones established for cardiovascular disease: high risk, <4%; intermediate risk, 4% to 8%; and low risk, >8%. Design Cross-sectional descriptive study. Setting Multicenter trial. Patients or Other Participants Deidentified data including complete erythrocyte fatty acid profile from the 2017–2018 season, age at time of testing, height, weight, and ethnicity were collected from 404 athletes. Main Outcome Measure(s) Omega-3 Index. Results About 34% of athletes (n = 138) had an Omega-3 Index considered high risk (<4%), and 66% (n = 266) had a risk considered intermediate (4%–8%). None had a low-risk Omega-3 Index. Conclusions The Omega-3 Index is a simple, minimally invasive test of ω-3 FA status. Our data indicate that football athletes may be deficient in the ω-3 FAs DHA and EPA. The fact that no athlete had an Omega-3 Index associated with low risk suggests football athletes may be at increased risk for cardiovascular disease in later life.

APA, Harvard, Vancouver, ISO, and other styles

10

Parker, John, Amanda Schellenberger, Amy Roe, Hellen Oketch-Rabah, and Angela Calderón. "Therapeutic Perspectives on Chia Seed and Its Oil: A Review." Planta Medica 84, no. 09/10 (March 13, 2018): 606–12. http://dx.doi.org/10.1055/a-0586-4711.

Full text

Abstract:

AbstractThe attraction of novel foods proceeds alongside epidemic cardiovascular disease, diabetes, obesity, and related risk factors. Dieticians have identified chia (Salvia hispanica) as a product with a catalog of potential health benefits relating to these detriments. Chia is currently consumed not only as seeds, but also as oil, which brings about similar effects. Chia seeds and chia seed oil are used mainly as a food commodity and the oil is also used popularly as a dietary ingredient used in various dietary supplements available in the U. S. market. Chia seed is rich in α-linolenic acid, the biological precursor to eicosapentaenoic acid, a polyunsaturated fatty acid, and docosahexaenoic acid. Because the body cannot synthesize α-linolenic acid, chia has a newfound and instrumental role in diet. However, the inconclusive nature of the scientific communityʼs understanding of its safety warrants further research and appropriate testing. The focus of this work is to summarize dietary health benefits of S. hispanica seed and oil to acknowledge concerns of adverse events from its ingestion, to assess current research in the field, and to highlight the importance of quality compendial standards to support safe use. To achieve this end, a large-scale literature search was partaken on the two well-known databases, PubMed and SciFinder. Hundreds of articles detailing such benefits as decreased blood glucose, decreased waist circumference and weight in overweight adults, and improvements in pruritic skin and endurance in distance runners have been recorded. These benefits must be considered within the appropriate circumstances.

APA, Harvard, Vancouver, ISO, and other styles

11

Holly, Langston T., Donald Blaskiewicz, Aiguo Wu, Cameron Feng, Zhe Ying, and Fernando Gomez-Pinilla. "Dietary therapy to promote neuroprotection in chronic spinal cord injury." Journal of Neurosurgery: Spine 17, no. 2 (August 2012): 134–40. http://dx.doi.org/10.3171/2012.5.spine1216.

Full text

Abstract:

Object The pathogenesis of cervical spondylotic myelopathy (CSM) is related to both primary mechanical and secondary biological injury. The authors of this study explored a novel, noninvasive method of promoting neuroprotection in myelopathy by using curcumin to minimize oxidative cellular injury and the capacity of omega-3 fatty acids to support membrane structure and improve neurotransmission. Methods An animal model of CSM was created using a nonresorbable expandable polymer placed in the thoracic epidural space, which induced delayed myelopathy. Animals that underwent placement of the expandable polymer were exposed to either a diet rich in docosahexaenoic acid and curcumin (DHA-Cur) or a standard Western diet (WD). Twenty-seven animals underwent serial gait testing, and spinal cord molecular assessments were performed after the 6-week study period. Results At the conclusion of the study period, gait analysis revealed significantly worse function in the WD group than in the DHA-Cur group. Levels of brain-derived neurotrophic factor (BDNF), syntaxin-3, and 4-hydroxynonenal (4-HNE) were measured in the thoracic region affected by compression and lumbar enlargement. Results showed that BDNF levels in the DHA-Cur group were not significantly different from those in the intact animals but were significantly greater than in the WD group. Significantly higher lumbar enlargement syntaxin-3 in the DHA-Cur animals combined with a reduction in lipid peroxidation (4-HNE) indicated a possible healing effect on the plasma membrane. Conclusions Data in this study demonstrated that DHA-Cur can promote spinal cord neuroprotection and neutralize the clinical and biochemical effects of myelopathy.

APA, Harvard, Vancouver, ISO, and other styles

12

Ramos-Campo, Domingo J., Vicente Ávila-Gandía, Fco Javier López-Román, José Miñarro, Carlos Contreras, Fulgencio Soto-Méndez, Joan C. Domingo Pedrol, and Antonio J. Luque-Rubia. "Supplementation of Re-Esteriﬁed Docosahexaenoic and Eicosapentaenoic Acids Reduce Inflammatory and Muscle Damage Markers after Exercise in Endurance Athletes: A Randomized, Controlled Crossover Trial." Nutrients 12, no. 3 (March 9, 2020): 719. http://dx.doi.org/10.3390/nu12030719.

Full text

Abstract:

This study aimed to analyse the effect of 10 weeks of a highly concentrated docosahexaenoic acid (DHA) + eicosapentaenoic (EPA) supplementation (ratio 8:1) on strength deficit and inflammatory and muscle damage markers in athletes. Fifteen endurance athletes participated in the study. In a randomized, double-blinded cross-over controlled design, the athletes were supplemented with a re-esterified triglyceride containing 2.1 g/day of DHA + 240 mg/day of EPA or placebo for 10 weeks. After a 4-week wash out period, participants were supplemented with the opposite treatment. Before and after each supplementation period, participants performed one eccentric-induced muscle damage exercise training session (ECC). Before, post-exercise min and 24 and 48 h after exercise, muscle soreness, knee isokinetic strength and muscle damage and inflammatory markers were tested. No significant differences in strength deficit variables were found between the two conditions in any of the testing sessions. However, a significant effect was observed in IL1β (p = 0.011) and IL6 (p = 0.009), which showed significantly lower values after DHA consumption than after placebo ingestion. Moreover, a significant main effect was observed in CPK (p = 0.014) and LDH-5 (p = 0.05), in which significantly lower values were found after DHA + EPA consumption. In addition, there was a significant effect on muscle soreness (p = 0.049), lower values being obtained after DHA + EPA consumption. Ten weeks of re-esterified DHA + EPA promoted lower concentrations of inflammation and muscle damage markers and decreased muscle soreness but did not improve the strength deficit after an ECC in endurance athletes.

APA, Harvard, Vancouver, ISO, and other styles

13

Huyben, David, Simona Rimoldi, Chiara Ceccotti, Daniel Montero, Monica Betancor, Federica Iannini, and Genciana Terova. "Effect of dietary oil from Camelina sativa on the growth performance, fillet fatty acid profile and gut microbiome of gilthead Sea bream (Sparus aurata)." PeerJ 8 (December 9, 2020): e10430. http://dx.doi.org/10.7717/peerj.10430.

Full text

Abstract:

Background In the last two decades, research has focused on testing cheaper and sustainable alternatives to fish oil (FO), such as vegetable oils (VO), in aquafeeds. However, FO cannot be entirely replaced by VOs due to their lack of omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFA), particularly eicosapentaenoic (EPA; 20:5n-3) and docosahexaenoic (DHA; 22:6n-3) acids. The oilseed plant, Camelina sativa, may have a higher potential to replace FO since it can contains up to 40% of the omega-3 precursors α-linolenic acid (ALA; 18:3n-3) and linoleic acid (LA; 18:2n-6). Methods A 90-day feeding trial was conducted with 600 gilthead sea bream (Sparus aurata) of 32.92 ± 0.31 g mean initial weight fed three diets that replaced 20%, 40% and 60% of FO with CO and a control diet of FO. Fish were distributed into triplicate tanks per diet and with 50 fish each in a flow-through open marine system. Growth performance and fatty acid profiles of the fillet were analysed. The Illumina MiSeq platform for sequencing of 16S rRNA gene and Mothur pipeline were used to identify bacteria in the faeces, gut mucosa and diets in addition to metagenomic analysis by PICRUSt. Results and Conclusions The feed conversion rate and specific growth rate were not affected by diet, although final weight was significantly lower for fish fed the 60% CO diet. Reduced final weight was attributed to lower levels of EPA and DHA in the CO ingredient. The lipid profile of fillets were similar between the dietary groups in regards to total saturated, monounsaturated, PUFA (n-3 and n-6), and the ratio of n-3/n-6. Levels of EPA and DHA in the fillet reflected the progressive replacement of FO by CO in the diet and the EPA was significantly lower in fish fed the 60% CO diet, while ALA was increased. Alpha and beta-diversities of gut bacteria in both the faeces and mucosa were not affected by any dietary treatment, although a few indicator bacteria, such as Corynebacterium and Rhodospirillales, were associated with the 60% CO diet. However, lower abundance of lactic acid bacteria, specifically Lactobacillus, in the gut of fish fed the 60% CO diet may indicate a potential negative effect on gut microbiota. PICRUSt analysis revealed similar predictive functions of bacteria in the faeces and mucosa, although a higher abundance of Corynebacterium in the mucosa of fish fed 60% CO diet increased the KEGG pathway of fatty acid synthesis and may act to compensate for the lack of fatty acids in the diet. In summary, this study demonstrated that up to 40% of FO can be replaced with CO without negative effects on growth performance, fillet composition and gut microbiota of gilthead sea bream.

APA, Harvard, Vancouver, ISO, and other styles

14

Rossen, Larissa, Sarah Montgomery, Deborah Zibrik, Roger Dyer, Tim Oberlander, and Yvonne Lamers. "Blood DHA, Choline, and Lutein Concentrations and Their Correlation with Cognitive and Behavioral Outcomes in 18-Month Old Toddlers: Preliminary Findings." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 1065. http://dx.doi.org/10.1093/cdn/nzaa054_137.

Full text

Abstract:

Abstract Objectives The objective of this study was to investigate associations between key nutrients identified as critical for central nervous system development and function, but which are limited in the diet of toddlers, and neurodevelopmental outcomes in toddler-aged children. We hypothesize that higher concentrations of key nutrients are associated with higher neurocognitive development scores. Methods Cross-sectional baseline data were drawn from 18-month old toddlers residing in Vancouver, Canada, who participated in a partially randomized controlled trial investigating associations between feeding patterns, nutrient biomarker status, and neurodevelopmental outcomes. Cognitive and behavioural outcomes considered for this analysis included: The Bayley Scale of Infant Development (3rd Ed; BSID-III); Child Behavior Checklist (CBCL); Early Childhood Behavior Questionnaire Very Short Form (ECBQ); and the MacArthur-Bates Communicative Development Inventories (Words & Gestures and Words & Sentences; MCDI-WG & WS). Blood biomarkers of nutrients of interest included plasma concentration of ferritin, lutein, choline, vitamins A and D, and betaine, as well as docosahexaenoic acid (DHA) measured as a percentage of total fatty acids in red blood cells. Results Sixty-nine toddlers (34 boys, 35 girls) with preliminary data available had a mean gestational age at birth and birthweight of 39.5 weeks and 3.48 kg, respectively. Preliminary (unadjusted) findings show higher levels of DHA corresponded with lower scores of effortful control on the ECBQ (rho = –.35, P < .01) while higher levels of lutein were associated with higher scores on the MCDI-WG (rho = .33, P < .05). Conclusions These preliminary findings may reflect an important association between nutritional status and optimal brain function at 18-months of age, a period of life which is particularly sensitive to nutrient inadequacies. These findings require confirmation in a larger sample size and causality testing of the relationship in a dose-dependency trial. Funding Sources This study is supported by The University of British Columbia, and the British Columbia Children's Hospital Research Institute, Canada, and is funded by Société des Produits Nestlé S.A.

APA, Harvard, Vancouver, ISO, and other styles

15

Montgomery, Sarah, Larissa Rossen, Deborah Zibrik, Roger Dyer, Tim Oberlander, and Yvonne Lamers. "Plasma Choline Concentration Is Positively Correlated with Visual Acuity in 18-Month Old Toddlers: Preliminary Findings." Current Developments in Nutrition 4, Supplement_2 (May 29, 2020): 1045. http://dx.doi.org/10.1093/cdn/nzaa054_117.

Full text

Abstract:

Abstract Objectives Adequate dietary intake of key nutrients is critical for brain and eye development in the first 1000 days of life. In particular, docosahexaenoic acid (DHA) and lutein are known for their roles in the development of visual acuity during infancy and early childhood. Preliminary data suggest that choline may also play a role in visual acuity; however, little is known about choline's role in visual acuity during toddlerhood. We hypothesize thatbiomarkers for DHA, choline, and lutein status are positively correlated with visual acuity in toddler-aged children. Methods We studied cross-sectional baseline data from participants aged 18 months ± 2 weeks enrolled in a partially randomized controlled trial investigating associations between feeding patterns, nutrient biomarker status, and neurodevelopmental outcomes. Participants were recruited in Metro Vancouver, Canada. Visual acuity was measured using the Cardiff Acuity test with the logarithm of the minimum angle of resolution (LogMAR) as the measure of visual acuity. The child's confidence in test completion was rated using a 5-point Likert scale; test results with confidence scores below 3 were excluded from further analyses. Results Sixty-nine toddlers, with preliminary data available at the time of analysis, had an equal distribution of males and females, 68% were the first-born child, and 55%, 19%, and 26% were of European, Chinese or other ethnicity, respectively. Preliminary (unadjusted) findings showed a positive correlation between plasma choline and visual acuity (rho = 0.33, P < 0.05). No significant correlations were observed between visual acuity and DHA concentration (as a percentage of total fatty acids from red blood cells) nor between visual acuity and plasma lutein concentration. Conclusions Plasma choline may be positively associated with visual acuity at 18 months of age. These preliminary findings require confirmation in a larger sample size and testing of the causality of this relationship in a dose-dependency trial. Acknowledgment: We are grateful for Dr. Margaret Woodhouse's guidance in the methodology of the Cardiff Acuity test. Funding Sources This study is supported by The University of British Columbia, and the British Columbia Children's Hospital Research Institute and is funded by Société des Produits Nestlé S.A.

APA, Harvard, Vancouver, ISO, and other styles

16

Price, Candice (Allister), Donovan A. Argueta, Valentina Medici, Andrew A. Bremer, Vivien Lee, Marinelle V. Nunez, Guoxia X. Chen, et al. "Plasma fatty acid ethanolamides are associated with postprandial triglycerides, ApoCIII, and ApoE in humans consuming a high-fructose corn syrup-sweetened beverage." American Journal of Physiology-Endocrinology and Metabolism 315, no. 2 (August 1, 2018): E141—E149. http://dx.doi.org/10.1152/ajpendo.00406.2017.

Full text

Abstract:

Epidemiological and clinical research studies have provided ample evidence demonstrating that consumption of sugar-sweetened beverages increases risk factors involved in the development of obesity, Type 2 diabetes, and cardiovascular disease (CVD). Our previous study demonstrated that when compared with aspartame (Asp), 2 wk of high-fructose corn syrup (HFCS)-sweetened beverages provided at 25% of daily energy requirement was associated with increased body weight, postprandial (pp) triglycerides (TG), and fasting and pp CVD risk factors in young adults. The fatty acid ethanolamide, anandamide (AEA), and the monoacylglycerol, 2-arachidonoyl- sn-glycerol (2-AG), are two primary endocannabinoids (ECs) that play a role in regulating food intake, increasing adipose storage, and regulating lipid metabolism. Therefore, we measured plasma concentrations of ECs and their analogs, oleoylethanolamide (OEA), docosahexaenoyl ethanolamide (DHEA), and docosahexaenoyl glycerol (DHG), in participants from our previous study who consumed HFCS- or Asp-sweetened beverages to determine associations with weight gain and CVD risk factors. Two-week exposure to either HFCS- or Asp-sweetened beverages resulted in significant differences in the changes in fasting levels of OEA and DHEA between groups after the testing period. Subjects who consumed Asp, but not HFCS, displayed a reduction in AEA, OEA, and DHEA after the testing period. In contrast, there were significant positive relationships between AEA, OEA, and DHEA vs. ppTG, ppApoCIII, and ppApoE in those consuming HFCS, but not in those consuming Asp. Our findings reveal previously unknown associations between circulating ECs and EC-related molecules with markers of lipid metabolism and CVD risk after HFCS consumption.

APA, Harvard, Vancouver, ISO, and other styles

17

Garcia-Martinez, V., C. Lopez Sanchez, W. Hamed, W. Hamed, JH Hsu, R. Ferrer-Lorente, Maryam Alshamrani, et al. "Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Association of deletion allele of insertion/deletion polymorphism in alpha 2B adrenoceptor gene and hypertension with or without type 2 diabetes mellitus295Association of G1359A polymorphism of the endocannabinoid type 1 receptor (CNR1) with coronary artery disease (CAD) with type 2 diabetes mellitusCell growth, differentiation and stem cells - Vascular298Gamma-secretase inhibitor prevents proliferation and migration of ductus arteriosus smooth muscle cells: a role of Notch signaling in postnatal closure of ductus arteriosus299Mesenchymal stromal-like cells (MLCs) derived from induced pluripotent stem (iPS) cells: a promising therapeutic option to promote neovascularization300Sonic Hedgehog promotes mesenchymal stem cell differentiation to vascular smooth muscle cells in cardiovacsular disease301Proinflammatory cytokine secretion and epigenetic modification in endothelial cells treated LPS-GinfivalisCell death and apoptosis - Vascular304Mitophagy acts as a safeguard mechanism against human vascular smooth muscle cell apoptosis induced by atherogenic lipidsTranscriptional control and RNA species - Vascular307MicroRNA-34a role in vascular calcification308Local delivery of a miR-146a inhibitor utilizing a clinically applicable approach attenuates neointima formation after vascular injury309Long noncoding RNA landscape of hypoxic endothelial cells310Specific circulating microRNAs levels associate with hypertension, hyperglycemia and dysfunctional HDL in acute coronary syndrome patientsCytokines and cellular inflammation - Vascular313Phosphodiesterase5A up-regulation in vascular endothelium under pro-inflammatory conditions: a newly disclosed anti-inflammatory activity for the omega-3polyunsaturated aatty acid docosahexaenoic acid314Cardiovascular risk modifying with extra-low dose anticytokine drugs in rhematoid arthritis315Conversion of human M-CSF macrophages into foam cells reduces their proinflammatory responses to classical M1-polarizing activation316Lymphocytic myocarditis coincides with increased plaque inflammation and plaque hemorrhage in coronary arteries, facilitating myocardial infarction317Serum osteoprotegerin level predictsdeclined numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndromeGrowth factors and neurohormones - Vascular320Effect of gastrin-releasing peptide (GRP) on vascular inflammationSignal transduction - Heart323A new synthetic peptide regulates hypertrophy in vitro through means of the inhibition of nfkb324Inducible fibroblast-specific knockout of p38 alpha map kinase is cardioprotective in a mouse model of isoproterenol-induced cardiac hypertrophy325Regulation of beta-adrenoceptor-evoked inotropic responses by inhibitory G protein, adenylyl cyclase isoforms 5 and 6 and phosphodiesterases326Binding to RGS3 and stimulation of M2 muscarinic acetylcholine receptors modulates the substrate specificity of p190RhoGAP in cardiac myocytes327Cardiac regulation of post-translational modifications, parylation and deacetylation in LMNA dilated cardiomyopathy mouse model328Beta-adrenergic regulation of the b56delta/pp2a holoenzyme in cardiac myocytes through b56delta phosphorylation at serine 573Nitric oxide and reactive oxygen species - Vascular331Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1 and eNOS332Antioxidant therapy prevents oxidative stress-induced endothelial dysfunction and Enhances Wound Healing333Morphological and biochemical characterization of red blood cell in coronary artery diseaseCytoskeleton and mechanotransduction - Heart336Novel myosin activator, JSH compounds, increased myocardial contractility without chronotropic effect in ratsExtracellular matrix and fibrosis - Vascular339Ablation of Toll-like receptor 9 causes cardiac rupture after myocardial infarction by attenuating proliferation and differentiation of cardiac fibroblasts340Altered vascular remodeling in the mouse hind limb ischemia model in Factor VII activating protease (FSAP) deficiencyVasculogenesis, angiogenesis and arteriogenesis343Pro-angiogenic effects of proly-hydroxylase inhibitors and their potential for use in a novel strategy of therapeutic angiogenesis for coronary total occlusion344Nrf2 drives angiogenesis in transcription-independent manner: new function of the master regulator of oxidative stress response345Angiogenic gene therapy, despite efficient vascular growth, is not able to improve muscle function in normoxic or chronically ischemic rabbit hindlimbs -role of capillary arterialization and shunting346Effect of PAR-1 inhibition on collateral vessel growth in the murine hind limb model347Quaking is a key regulator of endothelial cell differentiation, neovascularization and angiogenesis348"Emerging angiogenesis" in the chick chorioallantoic membrane (CAM). An in vivo study349Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis in vitro and in vivo via EMMPRINEndothelium352Reciprocal regulation of GRK2 and bradykinin receptor stimulation modulate Ca2+ intracellular level in endothelial cells353The roles of bone morphogenetic proteins 9 and 10 in endothelial inflammation and atherosclerosis354The contribution of GPR55 to the L-alpha-lysophosphatidylinositol-induced vasorelaxation in isolated human pulmonary arteries355The endothelial protective ACE inhibitor Zofenoprilat exerts anti-inflammatory activities through H2S production356A new class of glycomimetic drugs to prevent free fatty acid-induced endothelial dysfunction357Endothelial progenitor cells to apoptotic endothelial cell-derived microparticles ration differentiatesas preserved from reduced ejection fractionheart failure358Proosteogenic genes are activated in endothelial cells of patients with thoracic aortic aneurysm359Endothelin ETB receptors mediate relaxing responses to insulin in pericardial resistance arteries from patients with cardiovascular disease (CVD)Smooth muscle and pericytes362CX3CR1 positive myeloid cells regulate vascular smooth muscle tone by inducing calcium oscillations via activation of IP3 receptors363A novel function of PI3Kg on cAMP regulation, role in arterial wall hyperplasia through modulation of smooth muscle cells proliferation364NRP1 and NRP2 play important roles in the development of neointimal hyperplasia in vivo365Azithromycin induces autophagy in aortic smooth muscle cellsCoagulation, thrombosis and platelets368The real time in vivo evaluation of platelet-dependent aldosterone prothrombotic action in mice369Development of a method for in vivo detection of active thrombi in mice370The antiplatelet effects of structural analogs of the taurine chloramine371The influence of heparin anticoagulant drugs on functional state of human platelets372Regulation of platelet aggregation and adenosine diphosphate release by d dimer in acute coronary syndrome (in vitro study)Oxygen sensing, ischaemia and reperfusion375Sirtuin 5 mediates brain injury in a mouse model of cerebral ischemia-reperfusion376Abscisic acid: a new player in cardiomyocyte protection from ischaemia?377Protective effects of ultramicronized palmitoylethanolamide (PEA-um) in myocardial ischaemia and reperfusion injury in vivo378Identification of stem cell-derived cardiomyocytes using cardiac specific markers and additional testing of these cells in simulated ischemia/reperfusion system379Single-dose intravenous metformin treatment could afford significant protection of the injured rat kidney in an experimental model of ischemia-reperfusion380Cardiotoxicity of long acting muscarinic receptor antagonists used for chronic obstructive pulmonary disease381Dependence antioxidant potential on the concentration of amino acids382The impact of ischemia-reperfusion on physiological parameters,apoptosis and ultrastructure of rabbit myocardium with experimental aterosclerosisMitochondria and energetics385MicroRNA-1 dependent regulation of mitochondrial calcium uniporter (MCU) in normal and hypertrophied hearts386Mitochondrial homeostasis and cardioprotection: common targets for desmin and aB-crystallin387Overexpression of mitofusin-2 (Mfn2) and associated mitochondrial dysfunction in the diabetic heart388NO-dependent prevention of permeability transition pore (MPTP) opening by H2S and its regulation of Ca2+ accumulation in rat heart mitochondria389G protein coupled receptor kinase 2 (GRK2) is fundamental in recovering mitochondrial morphology and function after exposure to ionizing radiation (IR)Gender issues392Sex differences in pulmonary vascular control; focus on the nitric oxide pathwayAging395Heart failure with preserved ejection fraction develops when feeding western diet to senescence-accelerated mice396Cardiovascular markers as predictors of cognitive decline in elderly hypertensive patients397Changes in connexin43 in old rats with volume overload chronic heart failureGenetics and epigenetics400Calcium content in the aortic valve is associated with 1G>2G matrix metalloproteinase 1 polymorphism401Neuropeptide receptor gene s (NPSR1) polymorphism and sleep disturbances402Endothelin-1 gene Lys198Asn polymorphism in men with essential hypertension complicated and uncomplicated with chronic heart failure403Association of common polymorphisms of the lipoprotein lipase and pon1 genes with the metabolic syndrome in a sample of community participantsGenomics, proteomics, metabolomics, lipidomics and glycomics405Gene expression quantification using multiplexed color-coded probe pairs to determine RNA content in sporadic cardiac myxoma406Large-scale phosphorylation study of the type 2 diabetic heart subjected to ischemia / reperfusion injury407Transcriptome-based identification of new anti-inflammatory properties of the olive oil hydroxytyrosol in vascular endothelial cell under basal and proinflammatory conditions408Gene polymorphisms combinations and risk of myocardial infarctionComputer modelling, bioinformatics and big data411Comparison of the repolarization reserve in three state-of-the-art models of the human ventricular action potentialMetabolism, diabetes mellitus and obesity414Endothelial monocyte-activating polypeptide-II improves heart function in type -I Diabetes mellitus415Admission glucose level is independent predictor of impaired left ventricular function in patients with acute myocardial infarction: a two dimensional speckle-tracking echocardiography study416Association between biochemical markers of lipid profile and inflammatory reaction and stiffness of the vascular wall in hypertensive patients with abdominal obesity417Multiple common co-morbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress and myocardial stiffening418Investigating the cardiovascular effects of antiretroviral drugs in a lean and high fat/sucrose diet rat model of obesity419Statins in the treatment of non-alcoholic steatohepatitis (NASH). Our experience from a 2-year prospective study in Constanta County, Romania420Epicardial adipose tissue as a predictor of cardiovascular outcome in patients with ACS undergoing PCI?Arterial and pulmonary hypertension423Dependence between heart rhythm disorers and ID polymorphism of ACE gene in hypertensive patients424Molecular mechanisms underlying the beneficial effects of Urocortin 2 in pulmonary arterial hypertension425Inhibition of TGf-b axis and action of renin-angiotensin system in human ascending aorta aneurysms426Early signs of microcirculation and macrocirculation abnormalities in prehypertension427Vascular smooth muscle cell-expressed Tie-2 controls vascular tone428Cardiac and vascular remodelling in the development of chronic thrombo-embolic pulmonary hypertension in a novel swine modelBiomarkers431Arrhythmogenic cardiomyopathy: a new, non invasive biomarker432Can circulating microRNAs distinguish type 1 and type 2 myocardial infarction?433Design of a high-throughput multiplex proteomics assay to identify left ventricular diastolic dysfunction in diabetes434Monocyte-derived and P-selectin-carrying microparticles are differently modified by a low fat diet in patients with cardiovascular risk factors who will and who will not develop a cardiovascular event435Red blood cell distribution width assessment by polychromatic interference microscopy of thin films in chronic heart failure436Invasive and noninvasive evaluation of quality of radiofrequency-induced cardiac denervation in patients with atrial fibrillation437The effect of therapeutic hypothermia on the level of brain derived neurotrophic factor (BDNF) in sera following cardiopulmonary resustitation438Novel biomarkers to predict outcome in patients with heart failure and severe aortic stenosis439Biological factors linking depression and anxiety to cardiovascular disease440Troponins and myoglobin dynamic at coronary arteries graftingInvasive, non-invasive and molecular imaging443Diet composition effects on the genetic typing of the mouse ob mutation: a micro-ultrasound characterization of cardiac function, macro and micro circulation and liver steatosis444Characterization of pig coronary and rabbit aortic lesions using IV-OCT quantitative analysis: correlations with histologyGene therapy and cell therapy447Enhancing the survival and angiogenic potential of mouse atrial mesenchymal cells448VCAM-1 expression in experimental myocardial infarction and its relation to bone marrow-derived mononuclear cell retentionTissue engineering451Advanced multi layered scaffold that increases the maturity of stem cell-derived human cardiomyocytes452Response of engineered heart tissue to simulated ischemia/reperfusion in the presence of acute hyperglycemic conditions453Serum albumin hydrogels prevent de-differentiation of neonatal cardiomyocytes454A novel paintbrush technique for transfer of low viscosity ultraviolet light curable cyan methacrylate on saline immersed in-vitro sheep heart." Cardiovascular Research 111, suppl 1 (July 1, 2016): S56—S81. http://dx.doi.org/10.1093/cvr/cvw149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Coughlan, Gillian, Ryan Larsen, Min Kim, David White, Rachel Gillings, Michael Irvine, Andrew Scholey, et al. "APOE ε4 alters associations between docosahexaenoic acid and preclinical markers of Alzheimer’s disease." Brain Communications 3, no. 2 (April 1, 2021). http://dx.doi.org/10.1093/braincomms/fcab085.

Full text

Abstract:

Abstract Docosahexaenoic acid is the main long-chain omega-3 polyunsaturated fatty acids in the brain and accounts for 30−40% of fatty acids in the grey matter of the human cortex. Although the influence of docosahexaenoic acid on memory function is widely researched, its association with brain volumes is under investigated and its association with spatial navigation is virtually unknown. This is despite the fact that spatial navigation deficits are a new cognitive fingerprint for symptomatic and asymptomatic Alzheimer’s disease. We investigated the cross-sectional relationship between docosahexaenoic acid levels and the major structural and cognitive markers of preclinical Alzheimer’s disease, namely hippocampal volume, entorhinal volume and spatial navigation ability. Fifty-three cognitively normal adults underwent volumetric magnetic resonance imaging, measurements of serum docosahexaenoic acid (DHA, including lysophosphatidylcholine DHA) and APOE ε4 genotyping. Relative regional brain volumes were calculated and linear regression models were fitted to examine DHA associations with brain volume. APOE genotype modulated serum DHA associations with entorhinal cortex volume and hippocampal volume. Linear models showed that greater serum DHA was associated with increased entorhinal cortex volume, but not hippocampal volume, in non APOΕ ε4 carriers. APOE also interacted with serum lysophosphatidylcholine DHA to predict hippocampal volume. After testing interactions between DHA and APOE on brain volume, we investigated whether DHA and APOE interact to predict spatial navigation performance on a novel virtual reality diagnostic test for Alzheimer’s disease in an independent population of APOE genotyped adults (n = 46). APOE genotype modulated DHA associations with spatial navigation performance, showing that DHA was inversely associated with path integration in APOE ε4 carriers only. This exploratory analysis suggests that interventions aiming to increase DHA blood levels to protect against cognitive decline should consider APOE ε4 carrier status. Future work should focus on replicating our initial findings and establishing whether a specific dose of supplementary DHA, at a particular time in the preclinical disease course can have a positive impact on Alzheimer’s disease progression in APOE ε4 carriers.

APA, Harvard, Vancouver, ISO, and other styles

19

Bontjura, Sofriani D., Julius Pontoh, and Johnly A. Rorong. "KANDUNGAN LEMAK DAN KOMPOSISI ASAM LEMAK OMEGA-3 PADA IKAN KAKAP MERAH (Aphareus furca)." CHEMISTRY PROGRESS 12, no. 2 (January 20, 2020). http://dx.doi.org/10.35799/cp.12.2.2019.27931.

Full text

Abstract:

ABSTRAKIkan laut merupakan sumber makanan penghasil terbesar asam lemak omega-3. Senyawa ini telah banyak dibuktikan memberikan efek positif bagi kesehatan. Telah dilakukan penelitian untuk mengetahui kadar lemak dan komposisi asam lemak omega-3 pada badan ikan kakap merah (Aphareus furca). Pengujian kadar lemak dilakukan menggunakan metode ekstraksi rendering. Ekstrak minyak ikan yang diperoleh ditransesterifikasi basa menggunakan metode derivatisasi dan diinjeksikan pada alat kromatografi gas. Bagian badan ikan kakap merah mengandung lemak sebesar 0,06%. Kandungan asam lemak omega-3 sebesar 26,8% yang terdiri dari asam linolenat 2,4%, eikosatrienoat 4,3%, eikosapentaenoat (EPA) 0,9% dan dokosaheksaenoat (DHA) 19,2%. ABSTRACTFishes are the biggest food source of omega-3 fatty acids. This compound has been proven to have many positive effects on health. Research has been conducted to determine the fat content and composition of omega-3 fatty acids in the body of red snapper (Aphareus furca). Fat content testing is done using the rendering extraction method. Fish oil extract that was obtained were transesterified base using the derivatization method and injected on a gas chromatography device. The red snapper's body contains 0.06% fat. The omega-3 fatty acid content is 26.8% consisting of 2.4% linolenic acid, 4.3% eicosatrienoic acid, 0.9% eicosapentaenoic acid (EPA) and 19.2% docosahexaenoic acid (DHA).

APA, Harvard, Vancouver, ISO, and other styles

20

Rust, Bret, Shanon Casperson, Susan Raatz, and Matthew Picklo. "Saturated Fatty Acids from Dairy Increase Energy Expenditure Following an Acute Meal Challenge (P08-015-19)." Current Developments in Nutrition 3, Supplement_1 (June 1, 2019). http://dx.doi.org/10.1093/cdn/nzz044.p08-015-19.

Full text

Abstract:

Abstract Objectives Evidence suggests that the amount of fatty acid saturation and chain length affect fatty acid oxidation. Metabolism of unsaturated fatty acids may increase energy expenditure and shorter chain fatty acids may be selectively oxidized more readily. More data are needed to determine the impact of fatty acids, as they exist in dietary fats and oils, upon energy expenditure. We tested differences in energy expenditure after an acute meal challenge prepared with dietary fats and oils with fatty acids of differing chain lengths and saturation. The fats and oils used included olive oil (OO, for oleic acid, 18:1n-9), flaxseed oil (FL, for alpha-linolenic acid, 18:3n-3), sunflower oil (SO, for linoleic acid, 18:2n-6), heavy cream (HC, for saturated fatty acids) and fish oil (FO, for docosahexaenoic acid, 22:6n-3). Methods Healthy men and women (N = 27; 56% men; age: 26.8 ± 6.8; BMI: 29.1 ± 3.2), participated in a five-way crossover trial with intention to treat analysis. Body composition was assessed prior to the first study visit by dual X-ray absorptiometry. A standard three-day lead-in diet, prescribed for the participants’ energy needs, was consumed prior to testing. Subjects entered the metabolic chamber the evening before testing and were awakened at 6 AM for a resting metabolic rate measurement followed by a four-hour meal challenge. Test days were separated by at least 7 days. A 500 kcal smoothie with 30 g of test fat source was consumed within 15 min of an initial fasting blood draw. Metabolic rate (MR) and oxidation rates for fat, carbohydrate and protein were analyzed with proprietary software (PiLR™; MEI Research, Ltd.) for four hours after the challenge. Results MR standardized to fat free mass (FFM) and independent of FFM was greater after HC (1.64 ± 0.24 kcal/min) than FL (1.55 ± 0.26 kcal/min) and OO (1.53 ± 0.24 kcal/min) (P < 0.01) over the 4 hr postprandial period. Over four hours these differences accounted for 21.6 and 26.4 fewer kcal oxidized, respectively. Substrate oxidation rates did not differ between dietary fats. Conclusions In contrast to previously reported data, our initial data suggest dairy-derived saturated fatty acids may increase postprandial MR following an acute meal challenge. Funding Sources This work was supported by USDA-ARS project 3062-51000-053-00D.

APA, Harvard, Vancouver, ISO, and other styles

21

Davidson, Michael H., Jan Oscarsson, Mats Kvarnström, Larrye Loss, and Torbjörn Lundström. "Abstract 17223: Compositional Lipoprotein Changes With Omega-3 Carboxylic Acids in Patients With Hypertriglyceridemia Paired With Low HDL-C: A Substudy From the ESPRIT Trial." Circulation 132, suppl_3 (November 10, 2015). http://dx.doi.org/10.1161/circ.132.suppl_3.17223.

Full text

Abstract:

Introduction: STRENGTH (NCT02104817) is a 13,000-patient cardiovascular (CV) outcomes trial testing the hypothesis that high-CV-risk patients on statins with hypertriglyceridemia paired with low levels of high-density lipoprotein cholesterol (HDL-C) will have a reduction in incidence of major adverse CV events with omega-3 carboxylic acids (OM3-CA) 4 g/day compared with corn oil control. At present, the triglyceride (TG)-lowering mechanisms by which OM3-CA therapy may reduce CV risk are uncertain. Methods: In the ESPRIT trial (NCT01408303), patients (n=277) on statins who had fasting TG ≥200 mg/dL and <500 mg/dL and HDL-C <40 mg/dL for men and <45 mg/dL for women (also STRENGTH inclusion criteria) received either OM3-CA 4 g/day or olive oil (OO) 4 g/day for 6 weeks. The primary efficacy end point was percentage change in non-HDL-C from baseline to 6 weeks. We evaluated the lipoprotein compositional changes associated with non-HDL-C reduction. Results: Least-squares mean difference in HDL2:HDL3 ratio increased by 12% (p=0.004), while apolipoprotein (Apo)B100, ApoB48 and PCSK9 were not significantly affected. The sum of the change in the highly atherogenic subfractions, very-low-density lipoprotein cholesterol (VLDL-C) + small LDL-C + remnant lipoprotein-C, was strongly correlated with TG reduction (0.732; p<0.001) and percentage change in plasma eicosapentaenoic acid + docosahexaenoic acid + docosapentaenoic acid (–0.281; p<0.001). Conclusions: Compared with OO, OM3-CA 4 g/day significantly lowers non-HDL-C in patients with hypertriglyceridemia and low HDL-C by lowering VLDL-C, small LDL-C and remnant lipoprotein-C. Large LDL-C is raised without modifying ApoB100, ApoB48 or PCSK9 levels. STRENGTH will determine whether these lipoprotein compositional changes in this high-risk population will result in a CV benefit.

APA, Harvard, Vancouver, ISO, and other styles

22

Øyri, Linn K. L., Martin P. Bogsrud, Jacob J. Christensen, Stine M. Ulven, Anne Lise Brantsæter, Kjetil Retterstøl, Hilde K. Brekke, et al. "Novel associations between parental and newborn cord blood metabolic profiles in the Norwegian Mother, Father and Child Cohort Study." BMC Medicine 19, no. 1 (April 14, 2021). http://dx.doi.org/10.1186/s12916-021-01959-w.

Full text

Abstract:

Abstract Background More than one third of Norwegian women and men between 20 and 40 years of age have elevated cholesterol concentration. Parental metabolic health around conception or during pregnancy may affect the offspring’s cardiovascular disease risk. Lipids are important for fetal development, but the determinants of cord blood lipids have scarcely been studied. We therefore aimed to describe the associations between maternal and paternal peri-pregnancy lipid and metabolic profile and newborn cord blood lipid and metabolic profile. Methods This study is based on 710 mother–father–newborn trios from the Norwegian Mother, Father and Child Cohort Study (MoBa) and uses data from the Medical Birth Registry of Norway (MBRN). The sample included in this study consisted of parents with and without self-reported hypercholesterolemia the last 6 months before pregnancy and their partners and newborns. Sixty-four cord blood metabolites detected by nuclear magnetic resonance spectroscopy were analyzed by linear mixed model analyses. The false discovery rate procedure was used to correct for multiple testing. Results Among mothers with hypercholesterolemia, maternal and newborn plasma high-density lipoprotein cholesterol, apolipoprotein A1, linoleic acid, docosahexaenoic acid, alanine, glutamine, isoleucine, leucine, valine, creatinine, and particle concentration of medium high-density lipoprotein were significantly positively associated (0.001 ≤ q ≤ 0.09). Among mothers without hypercholesterolemia, maternal and newborn linoleic acid, valine, tyrosine, citrate, creatinine, high-density lipoprotein size, and particle concentration of small high-density lipoprotein were significantly positively associated (0.02 ≤ q ≤ 0.08). Among fathers with hypercholesterolemia, paternal and newborn ratio of apolipoprotein B to apolipoprotein A1 were significantly positively associated (q = 0.04). Among fathers without hypercholesterolemia, no significant associations were found between paternal and newborn metabolites. Sex differences were found for many cord blood lipids. Conclusions Maternal and paternal metabolites and newborn sex were associated with several cord blood metabolites. This may potentially affect the offspring’s long-term cardiovascular disease risk.

APA, Harvard, Vancouver, ISO, and other styles

23

Moran, C., A. Scotto di Palumbo, J. Bramham, A. Moran, B. Rooney, G. De Vito, and B. Egan. "EFFECTS OF A SIX-MONTH MULTI-INGREDIENT NUTRITION SUPPLEMENT INTERVENTION OF OMEGA-3 POLYUNSATURATED FATTY ACIDS, VITAMIN D, RESVERATROL, AND WHEY PROTEIN ON COGNITIVE FUNCTION IN OLDER ADULTS: A RANDOMISED, DOUBLE-BLIND, CONTROLLED TRIAL." Journal Of Prevention of Alzheimer's Disease, 2018, 1–9. http://dx.doi.org/10.14283/jpad.2018.11.

Full text

Abstract:

Objectives: To investigate the impact of a six-month multi-ingredient nutrition supplement intervention (Smartfish®), containing omega-3 polyunsaturated fatty acids (PUFAs), vitamin D, resveratrol, and whey protein, on cognitive function in Irish older adults. Design: Double-blind, randomised controlled trial (ClinicalTrials.gov: NCT02001831). A quantitative, mixed-model design was employed in which the dependent variable (cognitive function) was analysed with a between-subjects factor of group (placebo, intervention) and within-subjects factor of testing occasion (baseline, three-months, six-months). Setting: Community-based intervention including assessments conducted at University College Dublin, Ireland. Participants: Thirty-seven community-dwelling older adults (68-83 years; mean (x̄)= 75.14 years; standard deviation (SD)= 3.64; 18 males) with normal cognitive function (>24 on the Mini Mental State Examination) were assigned to the placebo (n= 17) or intervention (n= 20) via a block randomisation procedure. Intervention: Daily consumption for six-months of a 200mL liquid juice intervention comprising 3000mg omega-3 PUFAs [1500mg docosahexaenoic acid (DHA) and 1500mg eicosapentaenoic acid (EPA)], 10μg vitamin D3, 150mg resveratrol and 8g whey protein isolate. The placebo contained 200mL juice only. Measurements: A standardised cognitive assessment battery was conducted at baseline and follow-ups. Individual test scores were z-transformed to generate composite scores grouped into cognitive domains: executive function, memory, attention and sensorimotor speed. Motor imagery accuracy and subjective awareness of cognitive failures variables were computed from raw scores. Results: A hierarchical statistical approach was used to analyse the data; first, by examining overall cognitive function, then by domain, and then by individual test scores. Using mixed between-within subjects, analyses of variance (ANOVAs), no significant differences in overall cognitive function or composite cognitive domains were observed between groups over time. The only significant interaction was for Stroop Color-Word Time (p< 0.05). The intervention group demonstrated reduced task completion time at three- and six-month follow-ups, indicating enhanced performance. Conclusion: The present nutrition intervention encompassed a multi-ingredient approach targeted towards improving cognitive function, but overall had only a limited beneficial impact in the older adult sample investigated. Future investigations should seek to establish any potential clinical applications of such targeted interventions with longer durations of supplementation, or in populations with defined cognitive deficits.

APA, Harvard, Vancouver, ISO, and other styles

24

Steffens, D. C., M. E. Garrett, K. L. Soldano, D. R. McQuoid, A. E. Ashley-Koch, and G. G. Potter. "Genome-wide screen to identify genetic loci associated with cognitive decline in late-life depression." International Psychogeriatrics, July 9, 2020, 1–9. http://dx.doi.org/10.1017/s1041610220001143.

Full text

Abstract:

ABSTRACT Objective: This study sought to conduct a comprehensive search for genetic risk of cognitive decline in the context of geriatric depression. Design: A genome-wide association study (GWAS) analysis in the Neurocognitive Outcomes of Depression in the Elderly (NCODE) study. Setting: Longitudinal, naturalistic follow-up study. Participants: Older depressed adults, both outpatients and inpatients, receiving care at an academic medical center. Measurements: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) neuropsychological battery was administered to the study participants at baseline and a minimum of twice within a subsequent 3-year period in order to measure cognitive decline. A GWAS analysis was conducted to identify genetic variation that is associated with baseline and change in the CERAD Total Score (CERAD-TS) in NCODE. Results: The GWAS of baseline CERAD-TS revealed a significant association with an intergenic single-nucleotide polymorphism (SNP) on chromosome 6, rs17662598, that surpassed adjustment for multiple testing (p = 3.7 × 10−7; false discovery rate q = 0.0371). For each additional G allele, average baseline CERAD-TS decreased by 8.656 points. The most significant SNP that lies within a gene was rs11666579 in SLC27A1 (p = 1.1 × 10−5). Each additional copy of the G allele was associated with an average decrease of baseline CERAD-TS of 4.829 points. SLC27A1 is involved with processing docosahexaenoic acid (DHA), an endogenous neuroprotective compound in the brain. Decreased levels of DHA have been associated with the development of Alzheimer’s disease. The most significant SNP associated with CERAD-TS decline over time was rs73240021 in GRXCR1 (p = 1.1 × 10−6), a gene previously linked with deafness. However, none of the associations within genes survived adjustment for multiple testing. Conclusions: Our GWAS of cognitive function and decline among individuals with late-life depression (LLD) has identified promising candidate genes that, upon replication in other cohorts of LLD, may be potential biomarkers for cognitive decline and suggests DHA supplementation as a possible therapy of interest.

APA, Harvard, Vancouver, ISO, and other styles

25

Andrews, Karen, Pavel Gusev, Sushma Savarala, Phuong-Tan Tey, Laura Oh, Ronelle Bautista, Pamela Pehrsson, et al. "How Accurate Is the Labeled Content of Prescription Prenatal Multivitamin/mineral (MVM)? -an Analytical Pilot Study for the Dietary Supplement Ingredient Database (DSID) (OR14-08-19)." Current Developments in Nutrition 3, Supplement_1 (June 1, 2019). http://dx.doi.org/10.1093/cdn/nzz039.or14-08-19.

Full text

Abstract:

Abstract Objectives US national surveys report that pregnant women are at risk of dietary deficiency for several key nutrients, including calcium, iron, folate, and vitamin D. Most pregnant women take prenatal multivitamins (MVM). However intake studies have used only product label information, which may lead to incorrect estimates of their impact on nutrition status. It is unknown if the label information for prescription prenatal (RxP) MVM correctly reflects the composition of these products. The objective of this study was to investigate the relationship between labeled and analytically measured content of ingredients in RxP MVM. Methods From a list of 338 Rx prenatal MVM sold by retail and mail order pharmacies from 06–2015 to 06–2016, a selection of representative products was generated using random sampling weighted by market share. Multiple lots of 24 products, representing 61% of the market were tested by commercial laboratories for their vitamin, mineral and docosahexaenoic acid (DHA) content. Laboratories were selected based on the results from quality control materials, including National Institute of Standards and Technology Standard Reference Materials. Results The RxP MVM evaluated in this study varied in their labeled ingredient content. All RxP MVM labels listed folic acid, vitamins B-6, D, E and iron; 83–92% contained niacin, riboflavin, thiamin, and vitamins C, B-12, and zinc; and 71% contained calcium. Only 46–54% contained vitamin A, iodine and DHA. Analytical results showed mean overages of ≥20% for 6 vitamins (folic acid, niacin, riboflavin and vitamins A, B-12, D); 10–15% for vitamins B-6, C, E; and slightly below (−4%) label results for thiamin. For minerals and DHA, analytical content was close to labeled content, averaging 1–11% above label. Conclusions Many of the less expensive, highly consumed products were formulated without iodine or DHA despite recommendations for iodine supplementation from leading health authorities in the US and worldwide and data indicating that DHA may improve pregnancy outcomes. Analytical testing revealed that most RxP MVM had vitamin and mineral levels above label, with vitamin D the highest, averaging 29% above label. Thus, the intake of some nutrients from Rx prenatal MVM could be underestimated. Funding Sources NIH Office of Dietary Supplements and USDA Agricultural Research Service.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Docosahexaenoic acid – Testing'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles